InVitria Achieves cGMP Qualification Milestone


InVitria announces Lysobac is now available as a cGMP grade cell lysis reagent.


Lysobac is a recombinant and animal component free lysozyme used to manufacture biotherapeutics when a gentle microbial lysing agent is required to maintain product quality and integrity.


Fort Collins, CO February 8, 2011 – InVitria announces that its Lysobac cell lysing reagent is now manufactured under cGMP (Current Good Manufacturing Practice) standards at the Company’s Junction City, Kansas facility. Lysobac is a completely animal component free reagent that is substantially more effective and consistent than hen egg white lysozyme and complies with global regulatory standards for manufacturing biotherapeutics.

“Achievement of this milestone demonstrates InVitria’s commitment to the high quality standards that our customers expect,” said Shawn Smith, Vice President of Sales & Marketing.  

“Customers routinely inspect our facility and operations as part of their normal purchasing and vendor qualification process. With the introduction of cGMP-grade Lysobac, we are raising the bar for the quality of reagents used in biomanufacturing,” said Greg Unruh, Vice President of Manufacturing.

InVitria’s Lysobac is used in the manufacture of several products derived from microbial fermentation such as E. coli. Lysobac is more than four times more effective than hen egg white lysozyme and because it is derived from recombinant production, it delivers consistent performance. For more information about Lysobac, please visit www.Lysobac.com .

All biomanufacturing products from InVitria are animal component free and manufactured in Kansas. They include cell culture media supplements that optimize performance of cell lines including CHO, hybridoma, Vero, MDCK, mesenchymal, pluripotent, keratinocyte, chondrocyte and a wide array of stem and primary cell lines.

About InVitria (www.InVitria.com)

InVitria develops, manufactures and markets a portfolio of products used in cell culture, diagnostics and bioproduction. InVitria’s products address customer needs for defined, animal component free cell culture supplements in stem cell technology, regenerative medicine, biomanufacturing, diagnostics, biopharmaceutical formulation, cell-based vaccines and general life science research.

To obtain more information about InVitria’s product solutions, e-mail This e-mail address is being protected from spambots. You need JavaScript enabled to view it , visit us online at www.InVitria.com , or call toll-free 1-800-916-8311.

 
  • Blog: The Cell Culture Dish

    Cell Culture Media supplement Blog Strategies for Improving Viral Yield in Vaccine Manufacturing

    A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More

  • Latest News

    Invitria Cell Culture Media News InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference

    March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more